Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927419 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT01927419 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 142 participants.
The verdict
NCT01927419, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma
Interventions
- DRUG Placebo
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2013-08-23 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927419
The ClinicalTrials.gov registry entry for NCT01927419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01927419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927419 about?
NCT01927419 is a clinical study titled "Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma". The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma
What is the current status of trial NCT01927419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2013-08-23. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT01927419?
The interventions under investigation include: Placebo (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT01927419?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.